Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Novartis says Kesimpta gets EU approval in multiple sclerosis

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau

Novartis AG said on Tuesday Kesimpta (ofatumumab) has won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.

The Swiss drugmaker is developing and marketing the product under a license agreement with Genmab.

(Reporting by Michael Shields; editing by Brenna Hughes Neghaiwi)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.